Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02702492 | PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)(PANAMA) | terminated | Phase 1 | 60 | Karyopharm Therapeutics IncINDUSTRY | 2 | Nov 25, 2024 | clinicaltrials |
| NCT05525455 | TT-816 As Monotherapy or in Combination with a PD-1 Inhibitor in Patients with Advanced Cancers (SEABEAM) (MK3475-E88) | terminated | Phase 1 / Phase 2 | 9 | Teon Therapeutics, Inc.INDUSTRY | 1 | Nov 21, 2024 |
| NCT01217411 | RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer | terminated | Phase 1 / Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Nov 19, 2024 | clinicaltrials |
| NCT05228015 | Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors | terminated | Phase 1 | 67 | Ikena OncologyINDUSTRY | 3 | Nov 18, 2024 | clinicaltrials |
| NCT04060849 | Nozin in Preventing Respiratory Viral Infections in Patients Undergoing Stem Cell Transplant, PREV-NOSE STUDY | terminated | Phase 1 | 10 | Fred Hutchinson Cancer CenterOTHER | 1 | Nov 8, 2024 | clinicaltrials |
| NCT05394350 | A Study of MK-1088 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-1088-002) | terminated | Phase 1 / Phase 2 | 27 | Merck Sharp & Dohme LLCINDUSTRY | 5 | Nov 8, 2024 | clinicaltrials |
| NCT04795713 | Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1 | terminated | Phase 1 | 64 | Molecular Templates, Inc.INDUSTRY | 1 | Nov 4, 2024 | clinicaltrials |
| NCT03799003 | A Study of ASP1951 in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 119 | Astellas Pharma Global Development, Inc.INDUSTRY | 4 | Nov 1, 2024 | clinicaltrials |
| NCT04525014 | RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors(PIRATE) | terminated | Phase 1 | 2 | EpicentRx, Inc.INDUSTRY | 1 | Oct 31, 2024 | clinicaltrials |
| NCT03960060 | A Study of CCT301-59 CAR T Therapy in Adult Subjects With Recurrent or Refractory Solid Tumors(CAR) | terminated | Phase 1 | 9 | Shanghai PerHum Therapeutics Co., Ltd.INDUSTRY | 1 | Oct 28, 2024 | clinicaltrials |
| NCT03379259 | Study of BGB-A333 Alone and in Combination With Tislelizumab in Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 39 | BeiGeneINDUSTRY | 3 | Oct 26, 2024 | clinicaltrials |
| NCT04690699 | LUMINOS-103: A Basket Trial of Safety & Efficacy of Lerapolturev With or Without Checkpoint Inhibitors | terminated | Phase 1 / Phase 2 | 4 | Istari Oncology, Inc.INDUSTRY | 1 | Oct 24, 2024 | clinicaltrials |
| NCT03809624 | Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer(PDL1x41BB) | terminated | Phase 1 | 160 | Inhibrx Biosciences, IncINDUSTRY | 1 | Oct 23, 2024 | clinicaltrials |
| NCT02097225 | Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | terminated | Phase 1 | 22 | National Cancer Institute (NCI)NIH | 1 | Oct 16, 2024 | clinicaltrials |
| NCT03592264 | A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 68 | OBI Pharma, IncINDUSTRY | 1 | Oct 15, 2024 | clinicaltrials |
| NCT01127178 | Study of Poly (ADP-Ribose) Polymerase (PARP) Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 12 | Eisai Inc.INDUSTRY | 1 | Oct 10, 2024 | clinicaltrials |
| NCT04021277 | PS101-mediated ACT With Chemotherapy in Liver Metastases From Cancer of Gastrointestinal Origin(ACT) | terminated | Phase 1 | 11 | EXACT Therapeutics ASINDUSTRY | 2 | Oct 10, 2024 | clinicaltrials |
| NCT04683939 | Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors | terminated | Phase 1 / Phase 2 | 13 | BioNTech SEINDUSTRY | 2 | Oct 2, 2024 | clinicaltrials |
| NCT02994953 | A Phase Ib Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination With M9241(NHS-IL12) (JAVELIN IL-12)(COMBO) | terminated | Phase 1 | 52 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 7 | Sep 20, 2024 | clinicaltrials |
| NCT03604783 | Phase 1, First-in-human Study of Oral TP-1287 in Patients with Advanced Solid Tumors | terminated | Phase 1 | 74 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT02134067 | Dose-escalating, Safety, Tolerability and PK Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors | terminated | Phase 1 | 30 | Taiho Oncology, Inc.INDUSTRY | 1 | Sep 5, 2024 | clinicaltrials |
| NCT05824455 | A Clinical Study of IMP4297 Capsule (JS109) Combined With Irinotecan in the Treatment of Advanced Malignant Solid Tumors | terminated | Phase 1 / Phase 2 | 4 | Shanghai Jun Pai Ying Shi Therapeutics Co., Ltd.INDUSTRY | 1 | Sep 5, 2024 | clinicaltrials |
| NCT02448589 | An Investigation of TAS-119 Monotherapy | terminated | Phase 1 | 74 | Taiho Oncology, Inc.INDUSTRY | 5 | Sep 4, 2024 | clinicaltrials |
| NCT04747470 | Study to Assess the Effects of GS-3583 in Participants With Advanced Solid Tumors | terminated | Phase 1 | 13 | Gilead SciencesINDUSTRY | 1 | Sep 3, 2024 | clinicaltrials |
| NCT00791154 | QUILT-2.013: First-Line Treatment for Extensive Stage Small Cell Lung Cancer(SCLC) | terminated | Phase 1 / Phase 2 | 213 | NantCell, Inc.INDUSTRY | 0 | Aug 23, 2024 | clinicaltrials |
| NCT05996445 | A Study of XmAb®662 as Monotherapy or in Combination With Pembrolizumab in Advanced Solid Tumors | terminated | Phase 1 | 7 | Xencor, Inc.INDUSTRY | 1 | Aug 23, 2024 | clinicaltrials |
| NCT00819169 | QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors | terminated | Phase 1 / Phase 2 | 89 | NantCell, Inc.INDUSTRY | 0 | Aug 20, 2024 | clinicaltrials |
| NCT03355066 | A Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 82 | Biosplice Therapeutics, Inc.INDUSTRY | 1 | Aug 9, 2024 | clinicaltrials |
| NCT05764915 | A Phase I Study of RGT-264 in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 11 | Regor Pharmaceuticals Inc.INDUSTRY | 1 | Aug 1, 2024 | clinicaltrials |
| NCT03435250 | Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss | terminated | Phase 1 | 123 | Institut de Recherches Internationales ServierOTHER | 3 | Jul 25, 2024 | clinicaltrials |
| NCT04305249 | Safety and Preliminary Efficacy of ATG-017 Monotherapy or Combination Therapy With Nivolumab in Advanced Solid Tumors and Hematological Malignancies(ERASER) | terminated | Phase 1 | 36 | Antengene Therapeutics LimitedINDUSTRY | 1 | Jul 23, 2024 | clinicaltrials |
| NCT05338346 | A Study of ATG-018 (ATR Inhibitor) Treatment in Patients With Advanced Solid Tumors and Hematological Malignancies(ATRIUM) | terminated | Phase 1 | 22 | Antengene Discovery LimitedINDUSTRY | 1 | Jul 18, 2024 | clinicaltrials |
| NCT02110563 | Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma | terminated | Phase 1 | 50 | Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyINDUSTRY | 1 | Jul 11, 2024 | clinicaltrials |
| NCT05621525 | Phase I Study of the BBP-398 in Patients With Advance Solid Tumors | terminated | Phase 1 | 7 | LianBio LLCINDUSTRY | 1 | Jun 25, 2024 | clinicaltrials |
| NCT03301896 | Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies | terminated | Phase 1 | 45 | Novartis PharmaceuticalsINDUSTRY | 7 | Jun 20, 2024 | clinicaltrials |
| NCT04161391 | Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations | terminated | Phase 1 / Phase 2 | 41 | Turning Point Therapeutics, Inc.INDUSTRY | 2 | Jun 13, 2024 | clinicaltrials |
| NCT00963547 | A Study of MK-2206 in Combination With Trastuzumab and Lapatinib for the Treatment of HER2+ Solid Tumors (MK-2206-015) | terminated | Phase 1 | 33 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 4, 2024 | clinicaltrials |
| NCT05631327 | A JZP341 Study in Adult Participants With Advanced or Metastatic Solid Tumors | terminated | Phase 1 | 12 | Jazz PharmaceuticalsINDUSTRY | 1 | May 28, 2024 | clinicaltrials |
| NCT04190628 | Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors | terminated | Phase 1 | 53 | ABM Therapeutics CorporationINDUSTRY | 1 | May 21, 2024 | clinicaltrials |
| NCT04618393 | A Study of EMB-02 in Participants With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 47 | Shanghai EpimAb Biotherapeutics Co., Ltd.INDUSTRY | 3 | May 21, 2024 | clinicaltrials |
| NCT02663518 | A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors | terminated | Phase 1 | 249 | PfizerINDUSTRY | 2 | May 10, 2024 | clinicaltrials |
| NCT04250597 | Study of GNX102 in Patients With Advanced Solid Tumors | terminated | Phase 1 | 46 | GlycoNex, Inc.INDUSTRY | 2 | May 6, 2024 | clinicaltrials |
| NCT04167137 | Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Participants | terminated | Phase 1 | 32 | SynlogicINDUSTRY | 1 | May 3, 2024 | clinicaltrials |
| NCT05309512 | Clinical Study of KN052 in Chinese Subjects With Advanced Solid Tumors | terminated | Phase 1 | 15 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | May 1, 2024 | clinicaltrials |
| NCT04281420 | A Study of Evaluating Dual Inhibitor of PAK4 and NAMPT ATG-019 in Advanced Solid Tumors or Non-Hodgkin's Lymphoma(TEACH) | terminated | Phase 1 | 20 | Antengene Therapeutics LimitedINDUSTRY | 2 | Apr 30, 2024 | clinicaltrials |
| NCT04808362 | Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours(MYCure) | terminated | Phase 1 / Phase 2 | 22 | Peptomyc S.L.INDUSTRY | 1 | Apr 25, 2024 | clinicaltrials |
| NCT05581719 | A Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination With Anti-PD-1 Therapy for the Treatment of Advanced Solid Tumor Malignancy | terminated | Phase 1 / Phase 2 | 14 | Enlivex Therapeutics RDO Ltd.INDUSTRY | 2 | Apr 17, 2024 | clinicaltrials |
| NCT05148533 | A Study of Single Drug TJ011133 and Toripalimab Combine Treatment for Advanced Solid Tumor | terminated | Phase 1 / Phase 2 | 7 | TJ Biopharma Co., Ltd.INDUSTRY | 1 | Apr 15, 2024 | clinicaltrials |
| NCT05071183 | A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors | terminated | Phase 1 / Phase 2 | 9 | Turning Point Therapeutics, Inc.INDUSTRY | 1 | Apr 2, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Nov 25, 2024source: clinicaltrials